Echocardiographic progression of calcific aortic valve disease in patients with preexisting aortic valve sclerosis

Jasmin Shamekhi; Carina Uehre; Baravan Al-Kassou; Marcel Weber; Alexander Sedaghat; Atsushi Sugiura; Nihal Wilde; Matti Adam; Verena Veulemans; Malte Kelm; Stephan Baldus; Georg Nickenig; Sebastian Zimmer

doi:10.1101/2022.12.02.22283035

Abstract

Objective We aimed to evaluate echocardiographic parameters to predict CAVD progression.

Background Calcific aortic valve disease (CAVD) ranges from aortic valve sclerosis (ASc) with no functional impairment of the aortic valve to severe aortic stenosis (AS). It remains uncertain, which patients with ASc are at particular high risk of developing AS.

Methods We included a total of 153 patients with visual signs of ASc and peak flow velocity (Vmax.) below 2.5m/s at baseline echocardiography. Progression of CAVD to AS was defined as an increase of the Vmax. ≥ 2.5m/s with a delta of ≥ 0.1m/s; stable ASc complied with a Vmax. below 2.5m/s and a delta < 0.1m/s. Finally, we compared clinical and echocardiographic parameters between these two groups.

Results The mean age at baseline was 73.5 (± 8.2) years and 66.7% were of male gender. After a mean follow-up of 1463 days, 57 patients developed AS, while 96 patients remained in the ASc group. The AS group showed significantly more calcification (p < 0.001) and thickening (p < 0.001) of the aortic valve cusps at baseline, although hemodynamics showed no evidence of AS in both groups (ASc group: Vmax. 1.6 ± 0.3 m/s versus AS group: Vmax. 1.9 ± 0.3 m/s; p < 0.001). Advanced calcification (OR (95% CI): 4.8 (1.5 − 15.9); p = 0.009) and a cusp thickness > 0.26cm (OR (95% CI): 16.6 (5.4 – 50.7); p < 0.001) were independent predictors for the development of AS.

Conclusion The acquisition of simple echocardiographic parameter may help to identify patients at particular high risk of developing AS.

Competing Interest Statement

Drs. G. Nickenig and S. Zimmer have received speaker honoraria from Abbott, Abiomed, Medtronic, Boston Scientific, and Edwards Lifesciences. V. Veulemans has received speaker honoraria, grants or travel supports from Medtronic and Edwards Lifesciences. The other authors report no conflicts of interest.

Funding Statement

G. Nickenig, S. Zimmer, S. Baldus, M. Kelm and V. Veulemans are supported by the Deutsche Forschungsgemeinschaft (SFB TRR Sonderforschungsbereich/Transregio] 259/1).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics committee of the Medical Faculty of the University of Bonn gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes